Advertisement

The Complex Interplay Between Inflammatory Bowel Disease and Malignancy

  • Jessica KimmelEmail author
  • Jordan Axelrad
Inflammatory Bowel Disease (M Regueiro, Section Editor)
  • 2 Downloads
Part of the following topical collections:
  1. Topical Collection on Inflammatory Bowel Disease

Abstract

Purpose of Review

Both the chronic inflammation in inflammatory bowel disease (IBD), and its treatment, can increase the risk of malignancy. There is also an increasing number of patients with current and prior cancer who require IBD treatment. Thus, there is a complex interplay between immunosuppressive treatment and monitoring for new and recurrent cancer.

Recent Findings

Vedolizumab and ustekinumab have not been shown to increase the risk of malignancy. Transplant data shows a potential risk with tofacitinib although rheumatoid arthritis data does not. IBD patients have been shown to tolerate chemotherapy, specifically with cytotoxic compared with hormonal chemotherapy. Patients with prior cancer are at increased risk of new or recurrent cancers; however, immunosuppression appears to be safe.

Summary

Emerging treatments for IBD have demonstrated acceptable safety profiles for malignancy risk, and immunosuppression appears to be safe for use in patients with current and prior malignancy. More data is still needed to assess long-term risk of malignancy in these patients, especially with newer treatments.

Keywords

Inflammatory bowel disease Crohn’s disease Ulcerative colitis Malignancy Cancer 

Notes

Compliance with Ethical Standards

Conflict of Interest

Dr. Kimmel declares no conflict of interest. Dr. Axelrad declares no conflict of interest.

Human and Animal Rights

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Loftus EV. Update on the incidence and prevalence of inflammatory bowel disease in the United States. Gastroenterol Hepatol (NY). 2016;12:704–7.Google Scholar
  2. 2.
    CDC-Epidemiology of the IBD-Inflammatory Bowel Disease. https://www.cdc.gov/ibd/IBD-epidemiology.htm. Accessed 11 Apr 2019.
  3. 3.
    CCFA IBD stats.pdf.Google Scholar
  4. 4.
    Olén O, Askling J, Sachs MC, Frumento P, Neovius M, Smedby KE, et al. Childhood onset inflammatory bowel disease and risk of cancer: a Swedish nationwide cohort study 1964-2014. BMJ. 2017;358:j3951.PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Kappelman MD, Farkas DK, Long MD, Erichsen R, Sandler RS, Sørensen HT, et al. Risk of cancer in patients with inflammatory bowel diseases: a nationwide population-based cohort study with 30 years of follow-up evaluation. Clin Gastroenterol Hepatol. 2014;12:265–73.e1.PubMedCrossRefGoogle Scholar
  6. 6.
    Wu X, Kiran RP, Remzi FH, Katz S, Mukewar S, Shen B. Preoperative pelvic radiation increases the risk for ileal pouch failure in patients with colitis-associated colorectal cancer. J Crohns Colitis. 2013;7:e419–26.PubMedCrossRefGoogle Scholar
  7. 7.
    Rubin DT, Huo D, Kinnucan JA, et al. Inflammation is an independent risk factor for colonic neoplasia in patients with ulcerative colitis: a case-control study. Clin Gastroenterol Hepatol. 2013;11:1601–8.e1.PubMedCrossRefGoogle Scholar
  8. 8.
    Hudesman D, Lichtiger S, Sands B. Risk of extraintestinal solid cancer with anti-TNF therapy in adults with inflammatory bowel disease: review of the literature. Inflamm Bowel Dis. 2013;19:644–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Beaugerie L, Itzkowitz SH. Cancers complicating inflammatory bowel disease. N Engl J Med. 2015;372:1441–52.PubMedCrossRefGoogle Scholar
  10. 10.
    Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer: a population-based study. N Engl J Med. 1990;323:1228–33.PubMedCrossRefGoogle Scholar
  11. 11.
    Choi CR, Ignjatovic-Wilson A, Askari A, et al. Low-grade dysplasia in ulcerative colitis: risk factors for developing high-grade dysplasia or colorectal cancer. Am J Gastroenterol. 2015;110:1461–71 quiz 1472.PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Le PN, Greer JB, Oikonomou I, et al. IBD LIVE case series-case 2: previous cancer in a patient with Crohn’s disease: is it appropriate to use biologics and immunosuppressants for IBD treatment? Inflamm Bowel Dis. 2015;21:1401–6.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Axelrad JE, Lichtiger S, Yajnik V. Inflammatory bowel disease and cancer: the role of inflammation, immunosuppression, and cancer treatment. World J Gastroenterol. 2016;22:4794–801.PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Burak K, Angulo P, Pasha TM, Egan K, Petz J, Lindor KD. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol. 2004;99:523–6.PubMedCrossRefGoogle Scholar
  15. 15.
    Guerra I, Bujanda L, Castro J, et al. Clinical characteristics, associated malignancies and management of primary sclerosing cholangitis in inflammatory bowel disease patients: a multicenter retrospective cohort study. J Crohns Colitis. 2019.  https://doi.org/10.1093/ecco-jcc/jjz094.PubMedCrossRefGoogle Scholar
  16. 16.
    Ruel J, Ko HM, Roda G, Patil N, Zhang D, Jharap B, et al. Anal neoplasia in inflammatory bowel disease is associated with HPV and perianal disease. Clin Transl Gastroenterol. 2016;7:e148.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Beaugerie L, Carrat F, Nahon S, et al. High risk of anal and rectal cancer in patients with anal and/or perianal Crohn’s disease. Clin Gastroenterol Hepatol. 2018;16:892–899.e2.PubMedCrossRefGoogle Scholar
  18. 18.
    Long MD, Martin CF, Pipkin CA, Herfarth HH, Sandler RS, Kappelman MD. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology. 2012;143:390–399.e1.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Beaugerie L, Brousse N, Bouvier AM, Colombel JF, Lémann M, Cosnes J, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374:1617–25.PubMedCrossRefGoogle Scholar
  20. 20.
    Nyboe Andersen N, Pasternak B, Basit S, Andersson M, Svanström H, Caspersen S, et al. Association between tumor necrosis factor-α antagonists and risk of cancer in patients with inflammatory bowel disease. JAMA. 2014;311:2406–13.PubMedCrossRefGoogle Scholar
  21. 21.
    Osterman MT, Sandborn WJ, Colombel J-F, Robinson AM, Lau W, Huang B, et al. Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn’s disease. Gastroenterology. 2014;146:941–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Kopylov U, Vutcovici M, Kezouh A, Seidman E, Bitton A, Afif W. Risk of lymphoma, colorectal and skin cancer in patients with IBD treated with immunomodulators and biologics: a Quebec claims database study. Inflamm Bowel Dis. 2015;21:1847–53.PubMedCrossRefGoogle Scholar
  23. 23.
    • Colombel J-F, Sands BE, Rutgeerts P, et al. The safety of vedolizumab for ulcerative colitis and Crohn’s disease. Gut. 2017;66:839–51 Vedolizumab does not appear to increase the risk of malignancy. PubMedCrossRefGoogle Scholar
  24. 24.
    Papp K, Gottlieb AB, Naldi L, Pariser D, Ho V, Goyal K, et al. Safety surveillance for ustekinumab and other psoriasis treatments from the psoriasis longitudinal assessment and registry (PSOLAR). J Drugs Dermatol. 2015;14:706–14.PubMedGoogle Scholar
  25. 25.
    • Sandborn WJ, Panés J, D’Haens GR, et al. Safety of tofacitinib for treatment of ulcerative colitis, based on 4.4 years of data from global clinical trials. Clin Gastroenterol Hepatol. 2018.  https://doi.org/10.1016/j.cgh.2018.11.035 Evaluates malignancy risk of tofactinib in ulcerative colitis trials. PubMedCrossRefGoogle Scholar
  26. 26.
    Mason M, Siegel CA. Do inflammatory bowel disease therapies cause cancer? Inflamm Bowel Dis. 2013;19:1306–21.PubMedCrossRefGoogle Scholar
  27. 27.
    Swoger JM, Regueiro M. Stopping, continuing, or restarting immunomodulators and biologics when an infection or malignancy develops. Inflamm Bowel Dis. 2014;20:926–35.PubMedCrossRefGoogle Scholar
  28. 28.
    Siegel CA. Lost in translation: helping patients understand the risks of inflammatory bowel disease therapy. Inflamm Bowel Dis. 2010;16:2168–72.PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Askling J, Brandt L, Lapidus A, Karlén P, Björkholm M, Löfberg R, et al. Risk of haematopoietic cancer in patients with inflammatory bowel disease. Gut. 2005;54:617–22.PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Jess T, Horváth-Puhó E, Fallingborg J, Rasmussen HH, Jacobsen BA. Cancer risk in inflammatory bowel disease according to patient phenotype and treatment: a Danish population-based cohort study. Am J Gastroenterol. 2013;108:1869–76.PubMedCrossRefGoogle Scholar
  31. 31.
    Lemaitre M, Kirchgesner J, Rudnichi A, Carrat F, Zureik M, Carbonnel F, et al. Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease. JAMA. 2017;318:1679–86.PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Afif W, Sandborn WJ, Faubion WA, Rahman M, Harmsen SW, Zinsmeister AR, et al. Risk factors for lymphoma in patients with inflammatory bowel disease: a case-control study. Inflamm Bowel Dis. 2013;19:1384–9.PubMedCrossRefGoogle Scholar
  33. 33.
    Magro F, Peyrin-Biroulet L, Sokol H, Aldeger X, Costa A, Higgins PD, et al. Extra-intestinal malignancies in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop (III). J Crohns Colitis. 2014;8:31–44.PubMedCrossRefGoogle Scholar
  34. 34.
    Askling J, Fahrbach K, Nordstrom B, Ross S, Schmid CH, Symmons D. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol Drug Saf. 2011;20:119–30.PubMedCrossRefGoogle Scholar
  35. 35.
    Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Price S, et al. Serious infection and mortality in patients with Crohn’s disease: more than 5 years of follow-up in the TREAT™ registry. Am J Gastroenterol. 2012;107:1409–22.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Ferraro S, Leonardi L, Convertino I, Blandizzi C, Tuccori M. Is there a risk of lymphoma associated with anti-tumor necrosis factor drugs in patients with inflammatory bowel disease? A systematic review of observational studies. Front Pharmacol. 2019;10:247.PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Narula N, Peerani F, Meserve J, et al. Vedolizumab for ulcerative colitis: treatment outcomes from the VICTORY consortium. Am J Gastroenterol. 2018;113:1345.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    • Hanauer SB, Sandborn WJ, Feagan BG, et al. IM-UNITI: 3 year efficacy, safety, and immunogenicity of ustekinumab treatment of Crohn’s disease. J Crohns Colitis. 2019.  https://doi.org/10.1093/ecco-jcc/jjz110 Evaluates malignancy risk of ustekinumab in Crohn’s disease trial. CrossRefGoogle Scholar
  39. 39.
    • Sands BE, Sandborn WJ, Panaccione R, et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2019;381:1201–14 Evaluates malignancy risk of ustekinumab in ulcerative colitis trial. PubMedCrossRefPubMedCentralGoogle Scholar
  40. 40.
    Vincenti F, Tedesco Silva H, Busque S, O’Connell P, Friedewald J, Cibrik D, et al. Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year. Am J Transplant. 2012;12:2446–56.PubMedCrossRefGoogle Scholar
  41. 41.
    Maneiro JR, Souto A, Gomez-Reino JJ. Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: systematic review, meta-analysis, and network meta-analysis. Semin Arthritis Rheum. 2017;47:149–56.PubMedCrossRefGoogle Scholar
  42. 42.
    Axelrad JE, Fowler SA, Friedman S, Ananthakrishnan AN, Yajnik V. Effects of cancer treatment on inflammatory bowel disease remission and reactivation. Clin Gastroenterol Hepatol. 2012;10:1021–7.e1.PubMedCrossRefGoogle Scholar
  43. 43.
    Rajca S, Seksik P, Bourrier A, Sokol H, Nion-Larmurier I, Beaugerie L, et al. Impact of the diagnosis and treatment of cancer on the course of inflammatory bowel disease. J Crohns Colitis. 2014;8:819–24.PubMedCrossRefGoogle Scholar
  44. 44.
    • Axelrad J, Kriplani A, Ozbek U, Harpaz N, Colombel J-F, Itzkowitz S, et al. Chemotherapy tolerance and oncologic outcomes in patients with colorectal cancer with and without inflammatory bowel disease. Clin Colorectal Cancer. 2017;16:e205–10 Evaluated tolerance of cancer treatment in IBD patients compared with non-IBD patients. PubMedCrossRefGoogle Scholar
  45. 45.
    Som A, Mandaliya R, Alsaadi D, Farshidpour M, Charabaty A, Malhotra N, et al. Immune checkpoint inhibitor-induced colitis: a comprehensive review. World J Clin Cases. 2019;7:405–18.PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Prieux-Klotz C, Dior M, Damotte D, Dreanic J, Brieau B, Brezault C, et al. Immune checkpoint inhibitor-induced colitis: diagnosis and management. Target Oncol. 2017;12:301–8.PubMedCrossRefGoogle Scholar
  47. 47.
    Bergqvist V, Hertervig E, Gedeon P, Kopljar M, Griph H, Kinhult S, et al. Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis. Cancer Immunol Immunother. 2017;66:581–92.PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Green S, Stock RG, Greenstein AJ. Rectal cancer and inflammatory bowel disease: natural history and implications for radiation therapy. Int J Radiat Oncol Biol Phys. 1999;44:835–40.PubMedCrossRefGoogle Scholar
  49. 49.
    Annede P, Seisen T, Klotz C, Mazeron R, Maroun P, Petit C, et al. Inflammatory bowel diseases activity in patients undergoing pelvic radiation therapy. J Gastrointest Oncol. 2017;8:173–9.PubMedPubMedCentralCrossRefGoogle Scholar
  50. 50.
    Chang BW, Kumar AMS, Koyfman SA, Kalady M, Lavery I, Abdel-Wahab M. Radiation therapy in patients with inflammatory bowel disease and colorectal cancer: risks and benefits. Int J Color Dis. 2015;30:403–8.CrossRefGoogle Scholar
  51. 51.
    • Shelton E, Laharie D, Scott FI, Mamtani R, Lewis JD, Colombel J-F, et al. Cancer recurrence following immune-suppressive therapies in patients with immune-mediated diseases: a systematic review and meta-analysis. Gastroenterology. 2016;151:97–109.e4 Study found no difference in risk of new or recurrent cancers with immunosuppressive regimens. PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Lin SC, Goldowsky A, Papamichael K, Cheifetz AS. The treatment of inflammatory bowel disease in patients with a history of malignancy. Inflamm Bowel Dis. 2019;25:998–1005.PubMedCrossRefGoogle Scholar
  53. 53.
    •• Beaugerie L, Carrat F, Colombel J-F, et al. Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer. Gut. 2014;63:1416–23 Evaluated risk factors for new or recurrent cancer in large number of IBD patients with prior cancer. PubMedCrossRefGoogle Scholar
  54. 54.
    Raaschou P, Söderling J, Turesson C, Askling J, ARTIS Study Group. Tumor necrosis factor inhibitors and cancer recurrence in Swedish patients with rheumatoid arthritis: a nationwide population-based cohort study. Ann Intern Med. 2018;169:291–9.PubMedCrossRefGoogle Scholar
  55. 55.
    Axelrad J, Bernheim O, Colombel J-F, Malerba S, Ananthakrishnan A, Yajnik V, et al. Risk of new or recurrent cancer in patients with inflammatory bowel disease and previous cancer exposed to immunosuppressive and anti-tumor necrosis factor agents. Clin Gastroenterol Hepatol. 2016;14:58–64.PubMedCrossRefGoogle Scholar
  56. 56.
    Pang AS, Hudesman D, Chang S, Axelrad JE. Su1849–risk of new or recurrent cancer in patients with inflammatory bowel disease and previous cancer exposed to ustekinumab. Gastroenterology. 2019;156:S-634–5.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2020

Authors and Affiliations

  1. 1.Division of Gastroenterology, Department of MedicineNew York University School of MedicineNew YorkUSA
  2. 2.Division of Gastroenterology, Department of Medicine, Inflammatory Bowel Disease Center at New York University Langone HealthNew York University School of MedicineNew YorkUSA

Personalised recommendations